News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS)' Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?



8/31/2017 7:14:55 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Joseph Jimenez, the chief executive of Novartis, is celebrating a triumph. The Food and Drug Administration approved Kymriah, a new treatment for kids with leukemia. But he’s also taking heat from all sides over his decision to charge $475,000 for the treatment, and, in a major first, to negotiate deals that charge only patients who go into remission. For Wall Street, the sum is 36% less than investors expected, and could stunt a whole field. For patients, it is still far too expensive.

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES